Ventilatory and cardiovascular effects of prostacyclin and 6-oxo-PGF1 alpha by inhalation.
D015121:6-Ketoprostaglandin F1 alpha; D000328:Adult; D000336:Aerosols; D000368:Aged; D001249:Asthma / Q000503:physiopathology*; D002986:Clinical Trials as Topic; D011464:Epoprostenol / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008168:Lung / Q000503:physiopathology*; D008297:Male; D008875:Middle Aged; D010919:Placebos; D011453:Prostaglandins; D011460:Prostaglandins F; D012138:Respiratory Therapy; D014465:Ultrasonics
D000336:Aerosols; D010919:Placebos; D011453:Prostaglandins; D011460:Prostaglandins F; D015121:6-Ketoprostaglandin F1 alpha; D011464:Epoprostenol